Life Scientist > Health & Medical

Mesoblast forms three-way cancer R&D tie-up

24 October, 2013 by Dylan Bushell-Embling

Mesoblast (ASX:MSB), Ziopharm Oncology and Intrexon have teamed up to develop a new class of cell-based cancer treatments, with an initial focus on lung cancer.


NHMRC 2013 grants announced

24 October, 2013 by Susan WIlliamson

The outcomes of the NHMRC 2013 grant round have been announced.


Imugene steps in to buy Biolife Science

23 October, 2013 by Dylan Bushell-Embling

Imugene (ASX:IMU) has agreed to buy Biolife Science, the cancer immunotherapy company that called off a backdoor ASX listing and capital raising earlier this year.


New Zealand's Innate moves to Australia

16 October, 2013 by Dylan Bushell-Embling

Innate Immunotherapeutics has moved its base from Auckland to Sydney as it prepares for Australian phase IIb trials of SPMS treatment candidate MIS416.


Ramaciotti Awards and a new human systems biology centre

16 October, 2013

The 2013 recipients of the biennial Ramaciotti Awards for biomedical research have been announced.


Translational Research Institute officially opened

15 October, 2013

Brisbane's new biomedical research institute, Translational Research Institute, has been officially opened by the Governor-General, Her Excellency the Honourable Quentin Bryce.


Starpharma's DEO shows reduced neurotoxicity

14 October, 2013 by Dylan Bushell-Embling

Starpharma's (ASX:SPL) DEO, a formulation of colon and colorectal cancer drug oxaliplatin, has demonstrated reduced neurotoxicity in lab trials comparing it to the original version.


Melbourne Uni licenses Parkinson's tech to start-up

11 October, 2013 by Dylan Bushell-Embling

Research from the University of Melbourne and the Florey Institute could be developed into a new class of drugs for neurodegenerative diseases.


Novogen acquires cancer drug tech from Genscreen

10 October, 2013 by Dylan Bushell-Embling

Novogen (ASX:NRT) has licensed Australian-developed drug technology with the potential to replace the popular class of chemotherapeutics that target the cytoskeleton of cancer cells.


2013 Victoria Prize rewards malaria researcher

10 October, 2013

Professor Alan Cowman from the Walter and Eliza Hall Institute has been awarded the 2013 Victoria Prize for Science and Innovation in recognition of his outstanding contributions in the quest to eradicate malaria.


UQ and LEO Pharma collaborate on skin cancer treatment

10 October, 2013

The University of Queensland (UQ) and global pharmaceutical company LEO Pharma have entered a strategic research collaboration to deliver new treatment options to skin cancer patients.


Bionomics' extra overseas expenses eligible for R&D Tax Incentive

08 October, 2013

Bionomics (ASX:BNO) has received additional decisions from Innovation Australia in relation to the company's applications for an advance finding under the R&D Tax Incentive.


Clinical Genomics acquires cancer-screening lab Enterix

08 October, 2013

Clinical Genomics recently acquired the US-based cancer screening company Enterix.


The 2013 Nobel Prize in Physiology or Medicine

08 October, 2013

Three scientists' work on a major transport system in cells has won them the 2013 Nobel Prize in Physiology or Medicine.


Mental Health Research Alliance

04 October, 2013

Queensland's key health research institutes have joined forces to create the Queensland Mental Health Research Alliance.


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd